![Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior](https://mma.prnewswire.com/media/1222835/SPRAVATO_Logo.jpg?p=facebook)
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
![SPRAVATO®: A New Option for Treatment-Resistant Depression - PAKC - Psychiatry Associates of Kansas City SPRAVATO®: A New Option for Treatment-Resistant Depression - PAKC - Psychiatry Associates of Kansas City](https://pakconline.com/wp-content/uploads/2023/01/kansas-city-ketamine-spravato-PAKC.webp)
SPRAVATO®: A New Option for Treatment-Resistant Depression - PAKC - Psychiatry Associates of Kansas City
![New Spravato FDA Approval Opens The Door to New Patients, Says Sandhya Prashad, M.D. - Sandhya Prashad, MD New Spravato FDA Approval Opens The Door to New Patients, Says Sandhya Prashad, M.D. - Sandhya Prashad, MD](https://sprashadmd.com/wp-content/uploads/2020/08/Spravato-_-Sandhya-Prashad-MD-social-post.png)
New Spravato FDA Approval Opens The Door to New Patients, Says Sandhya Prashad, M.D. - Sandhya Prashad, MD
![J&J depression spray Spravato, carrying big expectations and restrictions, scores FDA nod | Fierce Pharma J&J depression spray Spravato, carrying big expectations and restrictions, scores FDA nod | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1551886134/spravato.jpg?VersionId=1w_nLNSPD91igaX5OW4fYvbUVZY3kvgn)